Navigation Links
Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics
Date:10/28/2009

On the heels of the U.S. Food & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics, Quotient Biodiagnostics, Inc., today announced that it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as its distributor to customers in the Midwest.

Newtown, PA (PRWEB) October 28, 2009 -- On the heels of the U.S. Food & Drug Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics, Quotient Biodiagnostics, Inc., today announced that it has entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as its distributor to customers in the Midwest.
   
MAGI, a regional specialty distributor that covers 25 percent of the U.S., will augment Quotient's direct sales force by promoting the company's products and facilitating the order process within its territory, which will create access to key customer markets throughout the Midwest. Unlike many specialty distribution organizations, MAGI is ISO 13485:2003 certified and specializes in representing companies in blood, anesthesia, vascular access, respiratory, NICU/PICU, interventional and critical care areas of the acute care hospital setting.

For customers in the rest of the country, Quotient will sell products through its direct sales force and has signed an agreement with the Global Healthcare Exchange (GHX) to provide electronic order processing in all regions outside the Midwest. As a member of GHX, Quotient is now linked with 3800 hospitals nationwide for electronic order processing and invoicing allowing greater efficiency and reduced administration costs versus typical paper processing.

"This exclusive selling agreement partners us with a highly accomplished and experienced team to bring Quotient's transfusion diagnostics products to our customers in the Midwest," said Jeremy Stackawitz, President and CEO, Quotient Biodiagnostics. "MAGI's proven success in hospital blood banks and high level of customer service is a strong match with Quotient's strategic principles. Combined with GHX, Quotient is now well positioned to service accounts nationwide."

Quotient Biodiagnostics was formed earlier this year to directly commercialize its proprietary line of products under the trade name ALBAclone®. Quotient provides innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market to help ensure safe and reliable transfusions at a reasonable cost.

This first BLA includes products used in forward blood typing, namely Anti-A, Anti-B, Anti-AB, Anti-D, Anti-E, and Anti-c, as well as some rare anti-sera including Anti-k, Anti-M, Anti-N, Anti- Lea, Anti-Leb, and Anti-Lub - all monoclonal antibodies. Quotient also has two specialty products in its initial portfolio including the ALBAclone® Advanced Partial RhD Typing Kit which identifies weak and partial RhD types with result comparable to molecular analysis at a fraction of the cost, and the Quant-Rho® FITC Anti-D product that quantifies Fetal Maternal Hemorrhage without the tribulations of KB staining. In addition, Quotient has several applications pending before, or soon to be submitted to, the FDA to complete a full portfolio of manual reagents of nearly 60 products.

"MED Alliance Group is excited about the opportunity to represent Quotient Biodiagnostics. We believe our specialty sales force, which has been promoting solutions to blood bank and blood center customers for over ten years, will embrace Quotient Biodiagnostics' technologies and diligently represent them to our customers," said Michael Crawford, Chief Operating Officer, MED Alliance Group, Inc.

Those interested in learning more about Quotient Biodiagnostics and its line of products are encouraged to visit www.quotientbd.com, or call the customer service line 888-284-1901, or e-mail customer.service(at)quotientbd.com.

About Quotient Biodiagnostics
Quotient Biodiagnostics is the diagnostics division of Quotient Bioscience Group (United Kingdom), and through its wholly owned subsidiary, Alba Bioscience, brings over 30 years experience in the transfusion medicine market to the Group. Quotient will focus on providing innovative, high-quality and cost-effective solutions to the worldwide transfusion medicine market, helping to ensure safe and reliable blood transfusions. Quotient's goal is to develop innovative new products and technologies to serve the worldwide transfusion medicine market, build a commercial operation (initially in North America) to market and sell the Group's world leading range of blood typing and screening products and continue as an important supplier of key raw materials and innovative new products to the Original Equipment Manufacturers market.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3123734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance to Enter U.S. Transfusion Diagnostics Market
2. MedAppz Signs Agreement with MedAssets to Offer SAAS-based Electronic Health Record to MedAssets' Non-acute Customers
3. Chimps Show Signs of Culture
4. Pumping Up the Volume in the Face to Reduce Signs of Aging
5. Vicon Signs License Agreement with Microsoft to Develop New Medical Technology
6. Vicon signs license agreement with Microsoft to develop new medical technology
7. Capital BlueCross Reaches Out to Former Employees of Turbine Airfoil Designs
8. Pluromed, Inc. Signs Agreement with Boston Scientific
9. SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites
10. /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
11. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: